• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Oragenics Inc (NY: OGEN )

    1.020 +0.120 (+13.33%)
    Official Closing Price Updated: 8:00 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,119,570
    Open 0.9400
    Bid (Size) 0.9603 (9)
    Ask (Size) 1.010 (50)
    Prev. Close 0.9000
    Today's Range 0.9000 - 1.020
    52wk Range 0.8611 - 7.740
    Shares Outstanding 5,580,693
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical Trial
    Via Investor Brand Network
    EXCLUSIVE: Oragenics Completes Spray Dry Drug Manufacturing, Intranasal Device Filling For Anticipated Mid-Stage Study For Patients With Brain Injury
    Oragenics completes the formulation and filling of its nasal spray drug, ONP-002, for concussion treatment, aiming to launch a Phase 2a trial. 
    Via Benzinga

    Performance

    YTD
    -84.96%
    -84.96%
    1 Month
    -3.77%
    -3.77%
    3 Month
    -54.05%
    -54.05%
    6 Month
    -68.90%
    -68.90%
    1 Year
    -66.11%
    -66.11%

    More News

    Read More
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
    Via Investor Brand Network
    Exposures Product Safety
    “Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
    Via AB Newswire
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    OGEN Stock Earnings: Oragenics Reported Results for Q2 2024
    Via InvestorPlace
    OGEN Stock Earnings: Oragenics Reported Results for Q4 2023
    Via InvestorPlace
    Why Oragenics (OGEN) Shares Are Falling
    Via Benzinga
    OGEN Stock Earnings: Oragenics Reported Results for Q1 2024
    Via InvestorPlace
    As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
    Via FinancialNewsMedia
    EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Nasdaq Falls Over 100 Points; TJX Posts Upbeat Q1 Results
    Via Benzinga
    Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Gold Down Over 1%; Williams-Sonoma Posts Strong Earnings
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
    From Oragenics, Inc.
    Via Business Wire
    Oragenics, Inc. Files 10K and Provides Company Update
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
    From Oragenics, Inc.
    Via Business Wire
    Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
    From Oragenics, Inc.
    Via Business Wire
    Oragenics Announces Closing of Public Offering
    From Oragenics, Inc.
    Via Business Wire
    S&P 500 Edges Lower; ADT Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.